Key Takeaways The S&P 500 ended 0.2% higher on Monday, Jan. 13, 2025, ahead of this week's inflation data and the first wave ...

Moderna made a lot of money during the pandemic, but its post-pandemic prospects look bleak. Sales in 2025 could be down more than half from 2024 levels, according to Moderna's latest guidance ...

Moderna shares are trading higher by 3.1% Monday afternoon. The CDC reported a significant rise in acute respiratory ...

Biopharma executives were busy Monday, striking high-value deals and providing updates on cancer, obesity and vaccine ...

Moderna Inc. shares plunged after the company slashed its sales forecast for this year as it struggles with slow demand for its Covid and RSV vaccines. The Cambridge, Massachusetts-based company ...

Moderna laid out sales expectations for the coming year on Monday that were below even the much-diminished Wall Street expectations. The stock was falling 14% to $35.71 in premarket trading. Monday’s ...

Moderna's bird flu vaccine development, supported by a U.S. government grant, could be a game changer if the bird flu spreads ...

The U.S. federal government provided the requisite resources for vaccine development to companies like Moderna, but it also led the procurement and distribution efforts for several manufacturers.

Moderna and Pfizer are in talks with the federal ... “We continue to have active conversations with both manufacturers, and the negotiations are ongoing,” O’Connell said.

With a state grand jury report released Wednesday, Florida Gov. Ron DeSantis doubled down on the message he delivered often ...

Moderna projects $1.5 billion-$2.5 billion in 2025 revenue, with cash and investments estimated at $6 billion by year-end. 2024 product sales are approximately $3 billion-$3.1 billion, driven by $ ...

Stock-plunging mRNA vaccine maker, already in bed with feds on vaccine royalties, says booster not "causally" related without ...